BMRN
BioMarin Pharmaceutical Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -4.2% ·
aandelenstroom -6.6% ·
netto nieuwe posities -8.7%
· formule
Brede distributie: dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.42M | $84.45M | n/a | −2 |
| Q2 2026 | 135 | +4 | 146.70M | $8.39B | +11 | −8 |
| Q1 2026 | 135 | -4 | 142.18M | $8.03B | +5 | −10 |
| Q4 2025 | 138 | +3 | 154.93M | $9.20B | +4 | n/a |
| Q3 2025 | 23 | -1 | 108.93M | $5.90B | n/a | −2 |
| Q2 2025 | 22 | -2 | 113.78M | $6.25B | n/a | −2 |
| Q1 2025 | 21 | 0 | 70.58M | $4.99B | +1 | −1 |
| Q4 2024 | 21 | +1 | 67.83M | $4.46B | +1 | n/a |
| Q3 2024 | 19 | 0 | 57.19M | $4.02B | +2 | −2 |
| Q2 2024 | 19 | n/a | 53.80M | $4.43B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 22.05M | -8.2% | $1.19B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (passief) | 18.58M | -2.2% | $1.01B | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 3 | PRIMECAP Management ✦ | 15.23M | -3.4% | $824.82M | 0.6% | ▼ Trim | 6 | SEC ↗ |
| 4 | Dodge & Cox ✦ | 14.69M | -2.8% | $795.44M | 0.4% | ▼ Trim | 6 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passief) | 8.76M | -0.9% | $474.69M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Viking Global Investors ✦ | 8.32M | -32.3% | $450.73M | 1.2% | ▼ Trim | 6 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 5.93M | +6.3% | $321.28M | 0.2% | ▲ Add | 6 | SEC ↗ ×7 |
| 8 | Geode Capital Management ✦ (passief) | 3.54M | +1.9% | $191.29M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 2.63M | -7.3% | $142.29M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 2.29M | n/a | $124.08M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Renaissance Technologies ✦ | 1.89M | +4.8% | $102.56M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 1.38M | n/a | $74.76M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 13 | JPMorgan Chase ✦ | 1.20M | n/a | $64.89M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 14 | Citadel Advisors ✦ | 397.85K | +18.8% | $21.55M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | Fidelity (FMR) ✦ | 392.81K | -28.1% | $21.27M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 16 | Bridgewater Associates ✦ | 375.68K | +65.0% | $20.35M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 374.71K | +34.5% | $20.29M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 275.24K | -75.3% | $14.91M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 265.33K | +122.1% | $14.37M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 157.59K | +6.8% | $8.53M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 148.03K | +7.3% | $8.02M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 22 | Fisher Asset Management ✦ | 31.73K | +134.2% | $1.72M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 23 | GAMCO Investors ✦ | 13.15K | +64.4% | $712,204 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Norges Bank | $112.35M | was 0.0% |
| Marshall Wace | $4.61M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 549 houders, 183.01M aandelen, $10.09B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 17.56K aand · $1.16M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie